How many insider trades does FilingIQ track for IKT?

FilingIQ tracks 28 Form 4 insider transactions for IKT (Inhibikase Therapeutics, Inc.), covering filings from Dec 28, 2020 onwards. 3 of those were filed in the last 90 days.

Are IKT insiders net buyers or net sellers?

Across the full Form 4 history for IKT, 13 transactions (46%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IKT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IKT in?

Inhibikase Therapeutics, Inc. (IKT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $213.43M.

IKT insider trading

NasdaqCM Healthcare

Inhibikase Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

46% / 0%

Market cap

$213.43M

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Company website: www.inhibikase.com

IKT insider activity at a glance

FilingIQ has scored 28 insider transactions for IKT since Dec 28, 2020. The most recent filing in our index is dated Feb 21, 2026.

Across the full history, 13 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IKT insider trades is 58.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IKT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for IKT?: FilingIQ tracks 28 Form 4 insider transactions for IKT (Inhibikase Therapeutics, Inc.), covering filings from Dec 28, 2020 onwards. 3 of those were filed in the last 90 days.
Are IKT insiders net buyers or net sellers?: Across the full Form 4 history for IKT, 13 transactions (46%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IKT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IKT in?: Inhibikase Therapeutics, Inc. (IKT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $213.43M.

Methodology & sources

Every IKT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.